Four leading drugmakers were back in federal court on Thursday to challenge the constitutionality of the Medicare Drug Price Negotiation Program under the Inflation Reduction Act.

Bristol Myers Squibb, Novo Nordisk, Novartis and Johnson & Johnson presented their arguments to Judge Zahid N. Quraishi of the U.S. District Court for the District of New Jersey. This hearing was different from the others in that the court allowed the four companies to present their oral arguments in a single session.

If court observers are correct, they may not be any more successful than other pharmaceutical companies were in two previous lawsuits in which courts ruled against the plaintiffs. Judge Quraishi was particularly doubtful about the companies' position that the negotiation program amounted to an unconstitutional taking of their property, according to Law360. Endpoints News reported that the judge also seemed unconvinced that the negotiations were not voluntary.